Cambium Bio Advances Toward Pivotal Trials

Regeneus Ltd. (AU:CMB) has released an update.

Cambium Bio Limited (formerly Regeneus Ltd), a clinical-stage regenerative medicine company, has reported significant strides in its business operations, including the completion of a strategic merger and leadership reshuffle to bolster its ophthalmology focus. The company is advancing towards Phase 3 trials for its leading dry eye disease treatment, Elate Ocular®, and is preparing for an RMAT designation application with the FDA, which could accelerate the approval process. Financially, Cambium Bio has fortified its cash reserves through a $3.48 million capital raise and is reviewing additional funding needs in anticipation of its clinical trials.

For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.